association

Full identifier: http://purl.org/np/RARyaWqFDihdLWcjLx7vkuUqw3sAxxjZhtWYnjLTgKQTQ#association

Assigned to 1 class:

Minted in Nanopublication

 RARyaWqFDi comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RARyaWqFDi...#association association https://w3id.org/biolink/vocab/has_population_context has_population_context This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RARyaWqFDi...#context context .
This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RARyaWqFDi...#context context http://www.w3.org/2000/01/rdf-schema#label label "Adults" .
This is the identifier for this whole nanopublication. http://purl.org/np/RARyaWqFDi... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature.
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:51:58.348Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)